Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.
Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a clinical-stage biotechnology company advancing a pipeline of oral small molecule degrader medicines based on targeted protein degradation (TPD). This news page aggregates company announcements, clinical updates, collaboration developments and capital markets activity related to Kymera’s work in immunological and other serious diseases.
Readers can follow detailed updates on KT-621, Kymera’s investigational first-in-class oral STAT6 degrader in Phase 2 clinical testing for Type 2 inflammatory diseases such as atopic dermatitis and asthma. News items include Phase 1b and Phase 2 trial progress, biomarker and clinical endpoint data, and regulatory milestones such as U.S. FDA Fast Track designation for moderate to severe atopic dermatitis. Coverage also extends to KT-579, an investigational oral IRF5 degrader for immune-mediated conditions, as it moves from preclinical work toward first-in-human studies.
In addition to internal programs, this feed highlights updates on Kymera’s partnered assets, including the IRAK4 degrader KT-485/SAR447971 in collaboration with Sanofi for immuno-inflammatory diseases and the oral CDK2 molecular glue degrader program with Gilead Sciences for potential use in breast cancer and other solid tumors. Investors can also find information on public offerings of common stock, shelf registration statements, and other corporate events disclosed through press releases and SEC filings.
By reviewing Kymera news on this page, users can track clinical trial milestones, regulatory interactions, collaboration announcements and financing transactions that shape the company’s development trajectory. For those researching KYMR stock or the evolution of targeted protein degradation in immunology and oncology, this consolidated news view provides ongoing context around Kymera’s pipeline and corporate strategy.
Kymera Therapeutics (NASDAQ: KYMR) reported significant progress in its clinical trials for novel protein degrader drugs. In a Phase 1 trial, KT-474, an IRAK4 degrader, achieved up to 96% degradation in blood and 97% inhibition of pro-inflammatory cytokines. The FDA cleared its IND application for KT-333, its STAT3 degrader, expected to enter clinical trials by year-end 2021. The company will host a virtual R&D Day on December 16, announcing further data and plans for its drug pipeline.
Kymera Therapeutics (NASDAQ: KYMR) announced the presentation of preclinical data on its STAT3 degrader program at the upcoming Society for Immunotherapy of Cancer (SITC) and American Society of Hematology (ASH) Annual Meetings. The data focuses on the treatment potential for hematological malignancies and solid tumors. The lead candidate, KT-333, is nearing a Phase 1 trial. The findings suggest synergistic effects when combining STAT3 degraders with immune checkpoint inhibitors, promising advancements in treating previously undruggable cancers.
Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, announced its participation in several upcoming virtual investor conferences. Notable events include a panel discussion at the UBS conference on November 1, 2021, and fireside chats at the Credit Suisse and Stifel healthcare conferences on November 11 and 15, respectively. Kymera focuses on targeted protein degradation, with its Pegasus™ platform addressing high-impact targets for immune-inflammatory diseases and cancers. For more details, webcasts will be available on their website.
Kymera Therapeutics (NASDAQ: KYMR) announced promising results from its Phase 1 trial of KT-474, a selective IRAK4 degrader. The Single Ascending Dose (SAD) trial showed up to 96% mean reduction of IRAK4 in PBMC within 48 hours, and up to 97% inhibition of pro-inflammatory cytokines. KT-474 was well-tolerated across all dose levels, with no serious adverse events reported. The MAD portion is underway, evaluating daily dosing. Kymera plans to present additional data before year-end, advancing its aim to target immune-inflammatory diseases.
Kymera Therapeutics (NASDAQ: KYMR) announced a conference call and webcast on October 27 to review data from the Single Ascending Dose (SAD) phase of the KT-474 trial. This presentation will feature Dr. Jared Gollob, the Chief Medical Officer, and will begin at 8:30 a.m. ET, followed by the conference call at 10:30 a.m. ET. The event aims to discuss Kymera's advancements in targeted protein degradation therapies, particularly for immune-inflammatory diseases and malignancies, highlighting its innovative Pegasus™ platform.
Kymera Therapeutics (NASDAQ: KYMR) announced multiple presentations at the 4th Annual Targeted Protein Degradation Summit from October 26-29, 2021. Keynote presentations will detail safety, pharmacokinetics (PK), and pharmacodynamics (PD) data from the Single Ascending Dose (SAD) phase of the KT-474 Phase 1 trial in healthy volunteers. KT-474, an orally available IRAK4 degrader, targets immune-inflammatory diseases like rheumatoid arthritis. The company plans to present further data from the Multiple Ascending Dose (MAD) phase by year-end.
Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, announced participation in two upcoming investor conferences. The first is the Morgan Stanley 19th Annual Global Healthcare Conference, featuring a live webcast on September 9, 2021, at 1:15 p.m. ET. The second is the H.C. Wainwright 23rd Annual Global Investment Conference, with an on-demand presentation available from September 13, 2021, at 7:00 a.m. ET. Webcasts can be accessed on the Company's website, where archived versions will be available for 30 days.
Kymera Therapeutics (NASDAQ: KYMR) reported positive interim results from its Phase 1 trial of KT-474, a first-in-class oral IRAK4 degrader, demonstrating a 94% degradation rate. The company initiated dosing for the Multiple Ascending Dose (MAD) portion of the trial and expects Investigational New Drug Applications (IND) for KT-413 and KT-333 in 2H 2021. Following a successful follow-on offering, Kymera now has a pro forma cash position of $647 million to support ongoing development and pipeline expansion. Collaboration revenues rose to $18.5 million while net loss for Q2 2021 was $24.7 million.
Kymera Therapeutics (NASDAQ: KYMR) announced the appointments of Karen Weisbach as Vice President of People and Culture and Jolly Bhatia as Vice President of Quality. Weisbach brings over 15 years of HR experience from bluebird bio, focusing on talent strategies. Bhatia, with 25 years in quality oversight, previously held roles at X4 Pharmaceuticals and Alnylam Pharmaceuticals. These appointments are part of Kymera's effort to strengthen its capabilities in targeted protein degradation and expand its pipeline, which targets immune-inflammatory diseases and various cancers.
Summary not available.
FAQ
What is the current stock price of Kymera Therapeutics (KYMR)?
What is the market cap of Kymera Therapeutics (KYMR)?
